·Synthesis and confirmation of HTS active compounds
·Mother core design and improvement
·Lead compound optimization
• development of new drug structure-activity relationship based on in vivo and in vitro biological activity data and drug absorption, distribution, metabolism, excretion and toxicity data
• use metabolic analysis to improve the pharmacokinetic characteristics of rodents and achieve pharmacokinetic indicators in vivo
• achieve data indicators of toxicity and safety pharmacology of drugs to rodents through structural modification
• search for clinical candidates with the most ideal physicochemical properties and drug-forming properties through structural modification
• study on the preparation of synthesis process chemistry / amplification
• patent applications
·Clinical candidate drug selection
·Customized cooperation scheme according to customer requirements